基于临床特征、磁共振成像生物标志物和微小RNA的新型整合路径用于前列腺癌早期检测的前瞻性验证研究
这项前瞻性单中心队列研究纳入261例疑似前列腺癌患者,评估磁共振成像生物标志物和循环微小RNA作为活检分流检测的价值。整合临床数据、MRI生物标志物和微小RNA的路径在低疾病概率时提供最佳净获益,活检回避率约20%。主要局限为转诊中心单中心设计。
要点
- 整合临床数据、MRI生物标志物和微小RNA的路径在低疾病概率时活检回避率约20%。
- 178例完整队列中55例(30.9%)无前列腺癌,39例(21.9%)为GG1,84例(47.2%)为GG>1。
- 该整合路径在前列腺癌早期检测中可将患者准确分配至活检并进行风险分层。
核心结论
- 整合路径是一个经过验证的模型,将MRI生物标志物和微小RNA作为临床显著前列腺癌风险患者的活检前分流工具。
- 所提出的路径在避免不必要的活检方面显示出最高的净获益。
研究设计与样本
- 前瞻性单中心队列研究,纳入疑似前列腺癌患者,接受MRI、MRI引导融合活检(MRDB)和循环微小RNA检测。
- 采用基于网络的分析识别临床显著前列腺癌的MRI生物标志物和微小RNA驱动因子。
- 共261名男性入组并接受MRDB进行前列腺癌检测;178例患者构成完整队列。
主要发现
- 178例完整队列中,55例(30.9%)前列腺癌阴性,39例(21.9%)为分级分组(GG)1前列腺癌,84例(47.2%)为GG>1前列腺癌。
- 包含临床数据、MRI生物标志物和微小RNA的整合路径在低疾病概率时提供最佳净获益,活检回避率约20%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性为转诊中心的单中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PCa) is the most diagnosed cancer in men, with an increasing need to integrate noninvasive imaging and circulating microRNAs beyond prostate-specific antigen for screening and early detection. OBJECTIVE: To validate magnetic resonance imaging (MRI) biomarkers and circulating microRNAs as triage tests for patients directed to prostate biopsy, and to test different diagnostic pathways to compare their performance on patients' outcome, in terms of unnecessary biopsy avoidance. DESIGN, SETTING, AND PARTICIPANTS: A prospective single-center cohort study, enrolling patients with PCa suspicion who underwent MRI, MRI-directed fusion biopsy (MRDB), and circulating microRNAs, was conducted. A network-based analysis was used to identify MRI biomarkers and microRNA drivers of clinically significant PCa. INTERVENTION: MRI, MRDB, and blood sampling. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The decision curve analysis was exploited to assess the performance of the proposed diagnostic pathways and to quantify their benefit in terms of biopsy avoidance. RESULTS AND LIMITATIONS: Overall, 261 men were enrolled and underwent MRDB for PCa detection. A total of 178 patients represented the entire cohort: 55 (30.9%) were negative for PCa, 39 (21.9%) had grade group (GG) 1 PCa, and 84 (47.2%) had GG >1 PCa. The proposed integrated pathway, including clinical data, MRI biomarkers, and microRNAs, provided the best net benefit with a biopsy avoidance rate of about 20% at a low disease probability. The main limitation is the monocentric design in a referral center. CONCLUSIONS: The integrated pathway represents a validated model that sees MRI biomarkers and microRNAs as a prebiopsy triage of patients at a risk for clinically significant PCa. The proposed pathway showed the highest net benefit in terms of unnecessary biopsy avoidance. PATIENT SUMMARY: The proposed integrated pathway for early detection of prostate cancer (PCa) allows accurate patient allocation to biopsy and patients' stratification into risk group categories, reducing overdiagnosis and overtreatment of clinically insignificant PCa.
引用
- Pecoraro M, Catanzaro G, Conte F, et al. Prospective Validation Study of a Novel Integrated Pathway Based on Clinical Features, Magnetic Resonance Imaging Biomarkers, and MicroRNAs for Early Detection of Prostate Cancer. Eur Urol Oncol. 2023. PMID: 37270379. doi:10.1016/j.euo.2023.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。